Literature DB >> 24318806

Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis.

Kuang-Wei Huang1, Hsin-Bang Leu, Jiing-Chyuan Luo, Wan-Leong Chan, Ming-Chih Hou, Han-Chieh Lin, Fa-Yauh Lee, Yi-Chun Kuan.   

Abstract

BACKGROUND: End stage renal disease (ESRD) patients receiving hemodialysis (HD) have a higher risk of peptic ulcer bleeding (PUB). AIMS: Whether ESRD patients receiving peritoneal dialysis (PD) also carries a higher risk of PUB has not been studied.
METHODS: This was a cohort study using Taiwan's National Health Insurance research database, whereby 11,408 patients, including 2,239 PD, 2,328 HD, 2,267 chronic kidney disease (CKD) and 4,574 controls with age-sex matching were recruited. The log-rank test was used to analyze differences in accumulated PUB-free survival rates between groups. Cox proportional hazard regression was performed to evaluate independent risk factors for PUB in all the enrollees.
RESULTS: During the 7-year follow-up, PD and CKD patients had a significantly higher rate of PUB than matched controls. The risk of PUB between PD and CKD was not significantly different. Moreover, patients receiving HD carried a higher risk of PUB than those receiving PD, with CKD and controls (p all <0.05, by log-rank test). Cox proportional hazard regression analysis showed that CKD (HR 3.99, 95 % CI 2.24-7.13), PD (HR 3.71, 95 % CI 2.00-6.87) and HD (HR 11.96, 95 % CI 7.04-20.31) were independently associated with an increased risk of PUB. Being elderly, male, having hypertension, diabetes, cirrhosis, and nonsteroidal anti-inflammatory drugs and steroid use were other independent risk factors of PUB in all enrollees.
CONCLUSIONS: Patients with CKD and ESRD receiving PD or HD carried a higher risk for PUB. They should be screened for risk factors for PUB and receive some protective measures to prevent PUB.

Entities:  

Mesh:

Year:  2013        PMID: 24318806     DOI: 10.1007/s10620-013-2973-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Effect of aging on gastric mucosal defense mechanisms: ROS, apoptosis, angiogenesis, and sensory neurons.

Authors:  Jung Mook Kang; Nayoung Kim; Joo-Hyon Kim; Euichaul Oh; Bong-Yong Lee; Byoung Hwan Lee; Cheol Min Shin; Ji Hyun Park; Mi Kyoung Lee; Ryoung Hee Nam; Hee Eun Lee; Hye Seung Lee; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-19       Impact factor: 4.052

2.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

3.  Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking.

Authors:  J H Kurata; A N Nogawa
Journal:  J Clin Gastroenterol       Date:  1997-01       Impact factor: 3.062

4.  Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study.

Authors:  J-C Luo; H-B Leu; M-C Hou; C-C Huang; H-C Lin; F-Y Lee; F-Y Chang; W-L Chan; S-J Lin; J-W Chen
Journal:  Aliment Pharmacol Ther       Date:  2012-07-23       Impact factor: 8.171

5.  Protein oxidative stress and dyslipidemia in dialysis patients.

Authors:  Andresa Marques de Mattos; Larissa Vieira Marino; Paula Payão Ovidio; Alceu Afonso Jordão; Carla Cristina Almeida; Paula Garcia Chiarello
Journal:  Ther Apher Dial       Date:  2011-11-03       Impact factor: 1.762

6.  Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis.

Authors:  Slobodan M Jankovic; Jelena Aleksic; Sladjana Rakovic; Aleksandra Aleksic; Ivan Stevanovic; Natasa Stefanovic-Stoimenov; Marija Radosavljevic; Marina Kostic; Danka Tesic; Bojana Petrovic
Journal:  J Nephrol       Date:  2009 Jul-Aug       Impact factor: 3.902

7.  Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis.

Authors:  Jiing-Chyuan Luo; Hsin-Bang Leu; Kuang-Wei Huang; Chin-Chou Huang; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Shou-Dong Lee
Journal:  CMAJ       Date:  2011-11-14       Impact factor: 8.262

8.  Disturbed gastroduodenal motility in patients with active and healed duodenal ulceration.

Authors:  D D Kerrigan; N W Read; L A Houghton; M E Taylor; A G Johnson
Journal:  Gastroenterology       Date:  1991-04       Impact factor: 22.682

9.  Prevalence of Helicobacter pylori infection in long-term hemodialysis patients.

Authors:  Mitsushige Sugimoto; Kyoko Sakai; Masakazu Kita; Jiro Imanishi; Yoshio Yamaoka
Journal:  Kidney Int       Date:  2008-10-08       Impact factor: 10.612

10.  Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in patients on continuous ambulatory peritoneal dialysis.

Authors:  H B Steinhauer; B Günter; P Schollmeyer
Journal:  Eur J Clin Invest       Date:  1985-02       Impact factor: 4.686

View more
  14 in total

1.  Risk of peptic ulcer bleeding in patients with chronic kidney disease and end-stage renal disease receiving peritoneal or hemodialysis.

Authors:  Tomoyuki Kawada
Journal:  Dig Dis Sci       Date:  2014-10-25       Impact factor: 3.199

2.  Comparison of Subdural Hematoma Risk between Hemodialysis and Peritoneal Dialysis Patients with ESRD.

Authors:  I-Kuan Wang; Yu-Kai Cheng; Cheng-Li Lin; Chiao-Ling Peng; Che-Yi Chou; Chiz-Tzung Chang; Tzung-Hai Yen; Chiu-Ching Huang; Fung-Chang Sung; Chung Y Hsu
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-30       Impact factor: 8.237

3.  Re-bleeding After Endoscopic Hemostasis for Peptic Ulcer Bleeding: Is eNough SAID or Are Other Factors Important?

Authors:  Mitsuhiro Fujishiro; Yuichi Ikeda
Journal:  Dig Dis Sci       Date:  2016-06       Impact factor: 3.199

Review 4.  Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Authors:  Tatjana S Potpara; Charles J Ferro; Gregory Y H Lip
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

5.  Gastrointestinal bleeding in patients with renal failure under hemodialysis treatment: a single-center experience.

Authors:  Özgür Can; Gözde Koç; Sema Berk Ocak; Nursel Akbay; Emel Ahishali; Mustafa Canbakan; Gülizar Manga Şahin; Süheyla Apaydin
Journal:  Int Urol Nephrol       Date:  2017-01-25       Impact factor: 2.370

6.  When Should Antiplatelet Agents Be Resumed After Successful Endoscopic Hemostasis in Patients with Peptic Ulcer Bleeding?

Authors:  Jung-Wook Kim; Hyun Jin Park; Jae-Young Jang; Chi Hyuk Oh; Jae-Jun Shim; Chang Kyun Lee; Young Woon Chang
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

7.  Chronic Kidney Disease and Risk for Gastrointestinal Bleeding in the Community: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Junichi Ishigami; Morgan E Grams; Rakhi P Naik; Josef Coresh; Kunihiro Matsushita
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 8.237

8.  The Risk of Major Hemorrhage with CKD.

Authors:  Amber O Molnar; Sarah E Bota; Amit X Garg; Ziv Harel; Ngan Lam; Eric McArthur; Gihad Nesrallah; Jeffrey Perl; Manish M Sood
Journal:  J Am Soc Nephrol       Date:  2016-01-28       Impact factor: 10.121

9.  Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study.

Authors:  Yi-Che Lee; Shih-Yuan Hung; Hsi-Hao Wang; Hao-Kuang Wang; Chi-Wei Lin; Min-Yu Chang; Li-Chun Ho; Yi-Ting Chen; Ching-Fang Wu; Ho-Ching Chen; Wei-Ming Wang; Junne-Ming Sung; Yuan-Yow Chiou; Sheng-Hsiang Lin
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

10.  Validating a Patient-Reported Comorbidity Measure with Respect to Quality of Life in End-Stage Renal Disease.

Authors:  Maxi Robinski; Franz Strich; Wilfried Mau; Matthias Girndt
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.